ArticleOncology letters2026
Identification of non-oncology drugs with activity against inflammatory and triple-negative breast cancer cell lines.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) are subtypes of breast cancer with the lowest 5-year survival rates. One potential approach to increase survival rates for these cancers may be to identify tolerable and inexpensive daily maintenance therapies that could be administered in between standard of care treatments. The present study aimed to identify non-oncology drugs (NODs) that show activity against IBC/TNBC that could be repurposed for this use. Thus, a collection of NODs were screened and curated from a published database using cell line SUM-149, which is both an IBC and TNBC cell line (TN-IBC). In a parallel screening approach, a subset of these NODs were tested for activity against two other TNBC cell lines. Together, 15 drugs with activity against this IBC cell line were identified and grown as spheroids. A number of these drugs have not been previously identified as having activity in an IBC cell line. In addition, eight of these were understudied for TNBC and, therefore, they were tested against three TNBC cell lines grown as spheroids, resulting in variable breadth of activities. Drug potency (GI
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.